This suggests that BRAF V600E is a potential therapeutic target for a small subset of patients with synovial sarcoma, and it warrants screening given the encouraging tumour-agnostic activity of the combination of dabrafenib with trametinib and its tumour-agnostic regulatory approval [83]. The gene discussed is BRAF; the disease is synovial sarcoma.